Study
Shingles Vaccine May Reduce Dementia Risk in Older Adults
Receiving the shingles vaccine was linked to a 24% lower risk of dementia in seniors over four years.
Summary
In plain language
A recent study suggests that getting the shingles vaccine may help lower the risk of developing dementia for older adults. Researchers at Brown University found that seniors who received the Shingrix vaccine were 24% less likely to be diagnosed with dementia within four years compared to those who did not get vaccinated. The study involved more than 500,000 adults aged 66 and older who stayed in skilled nursing facilities. While the reasons for this protective effect are still being explored, the findings offer hope that the vaccine could support brain health. Seniors should consider discussing the benefits of the shingles vaccine with their healthcare providers.
Details
Use the full description to understand the study design, methods, and the limits of the findings.
This study looked at the medical records of over 500,000 seniors who were admitted to skilled nursing facilities across the U.S. between 2017 and 2022.
Researchers compared dementia rates between those who received the Shingrix vaccine and those who did not.
They found a significant 24% reduction in dementia diagnoses among those who were vaccinated.
Limitations include the possibility that those vaccinated were generally healthier, which could affect results.
For seniors, getting vaccinated not only helps prevent shingles but may also offer additional brain health benefits. It's important to talk to healthcare providers about the potential advantages of receiving the shingles vaccine.
Full Study
Open the original publication for the complete methods, outcomes, and source material.
Shingles Vaccine May Reduce Dementia Risk in Older Adults
Published September 2026
Opens at the publisher · external site · may require institutional access
Research Quality Score
Scored September 22, 2026 using rubric mq-1.8_2026-07-06.
Assessment
The study used a robust observational design (target trial emulation) and adjusted for confounders, but lacked randomization and blinding. Statistical methods were standard but lacked power calculations. Transparency was limited by the absence of pre-registration. The study was funded by GlaxoSmithKline, affecting independence. The population was relevant to seniors, but journal quality could not be assessed.
Category Breakdown
| Category | Score | Rating |
|---|---|---|
| Study design | 6.7/10 | |
| Bias control | 3.3/10 | |
| Statistical methods | 5.0/10 | |
| Reporting completeness | 5.0/10 | |
| Conflicts & funding | 5.0/10 | |
| Replication | 0.0/10 | |
| Relevance to chosen population | 10.0/10 | |
| Journal Reliability | 5.0/10 |
Additional Notes
The study analyzed health records of over 500,000 adults aged 66+ and found that those vaccinated with Shingrix had a 24% lower risk of dementia over four years compared to unvaccinated individuals.
Assessed on the study's full text across 8 quality dimensions; conflict-of-interest disclosures were reviewed.
Conditions This Research Covers
These condition pages help connect the paper back to the real-world health concerns it addresses.
Dementia
Dementia is a broad term used to describe a decline in cognitive function that interferes with daily life. It predominantly affects older adults, with symptoms like memory loss and changes in behavior. Dementia is not a normal part of aging, and early diagnosis is crucial for management.
Alzheimer's Disease
Alzheimer's disease is a progressive neurological disorder that affects memory, thinking, and behavior. It primarily impacts older adults, with symptoms gradually worsening over time. As the most common cause of dementia, Alzheimer's can lead to a significant decline in daily functioning and independence.
Take the next step
Build a personalized plan using research-backed studies, conditions, and treatments.